TrialThe pharmacogenomics journal2018

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.

C F Spraggs et al.PubMed ↗Publisher ↗

No numbers read from the abstract.